RML vs INCY Comparison

Resolution Minerals Ltd is a mineral exploration company engaged in the acquisition, exploration, and development of precious and battery metals, such as antimony, gold, copper, and uranium. It is focused on critical defense minerals, together with gold and silver, to deliver a solution for domestic antimony supply to the U.S defense industry. The Horse Heaven antimony-tungsten-gold project in Idaho is Resolution's flagship project, adjoining Perpetua's Stibnite antimony-gold project.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.